Roberto Pili
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1650 Orleans Street
CRB1 Room 1M52
Baltimore
USA
Name/email consistency: high
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M.A., Rudek, M.A. Br. J. Cancer (2012)
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. Pili, R., Häggman, M., Stadler, W.M., Gingrich, J.R., Assikis, V.J., Björk, A., Nordle, O., Forsberg, G., Carducci, M.A., Armstrong, A.J. J. Clin. Oncol. (2011)
- Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Pili, R., Rosenthal, M.A., Mainwaring, P.N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S., Clingan, P. Clin. Cancer Res. (2010)